Epigenetic targets in human neoplasms

Epigenomics

Volumn 2, Issue 2, 2010, Pages 221-232

  Fandy, Tamer E ^a   Gore, Steven D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

DNA methyltransferases inhibitor; epigenetics; epigenome; histone acetylation; histone methylation; miRNA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; OLIGONUCLEOTIDE; VALPROIC ACID;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; CANCER GROWTH; CELL PROLIFERATION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; LEUKEMIA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR GENE;

DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HISTONES; HUMANS; MICRORNAS; NEOPLASMS;

EID: 77954104642     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.1     Document Type: Review

References (100)

1. Bhaumik SR, Smith E, Shilatifard A: Covalent modifcations of histones during development and disease pathogenesis. Nat. Struct. Mol. Biol. 14(11), 1008-1016 (2007).
2. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128(4), 683-692 (2007).
3. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
4. Probst AV, Dunleavy E, Almouzni G: Epigenetic inheritance during the cell cycle. Nat. Rev. Mol. Cell Biol. 10(3), 192-206 (2009).
5. Henikoff S: Nucleosome destabilization in the epigenetic regulation of gene expression. Nat. Rev. Genet. 9(1), 15-26 (2008).
6. Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R: Lymphocytes from patients with Type 1 diabetes display a distinct profle of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 57(12), 3189-3198 (2008).
7. Chao MJ, Ramagopalan SV, Herrera BM et al.: Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. Hum. Mol. Genet. 18(2), 261-266 (2009).
8. Javierre BM, Esteller M, Ballestar E: Epigenetic connections between autoimmune disorders and haematological malignancies. Trends Immunol. 29(12), 616-623 (2008).
9. Nardone G, Compare D, De Colibus P, de Nucci G, Rocco A: Helicobacter pylori and epigenetic mechanisms underlying gastric carcinogenesis. Dig. Dis. 25(3), 225-229 (2007).
10. Olivier M, Aggarwal A, Allen J et al.: A high-resolution radiation hybrid map of the human genome draft sequence. Science 291(5507), 1298-1302 (2001).
11. American Association for Cancer Research Human Epigenome Task Force, European Union Network of Excellence, Scientifc Advisory Board: Moving AHEAD with an international human epigenome project. Nature 454(7205), 711-715 (2008).
12. Madhani HD, Francis NJ, Kingston RE et al.: Epigenomics: a roadmap, but to where? Science 322(5898), 43-44 (2008).
13. Pennisi E: Research funding. are epigeneticists ready for big science? Science 319(5867), 1177 (2008).
14. Bird A: Perceptions of epigenetics. Nature 447(7143), 396-3988 (2007).
15. Das C, Lucia MS, Hansen KC, Tyler JK: CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459(7243), 113-117 (2009).
16. Gill G: SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev. 18(17), 2046-2059 (2004).
17. Shilatifard A: Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr. Opin. Cell Biol. 20(3), 341-348 (2008).
18. Weake VM, Workman JL: Histone ubiquitination: triggering gene activity. Mol. Cell 29(6), 653-663 (2008).
19. Van Lint C, Emiliani S, Verdin E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5(4-5), 245-253 (1996).
20. Dai Y, Rah man i M, Dent P, Grant S: Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-KB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-jun N-terminal kinase 1 activation. Mol. Cell. Biol. 25(13), 5429-5444 (2005).
21. Kovacs JJ, Murphy PJ, Gaillard S et al.: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18(5), 601-607 (2005).
22. Marks PA, Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 107(4), 600-6088 (2009).
23. Nusinzon I, Horvath CM: Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl Acad. Sci. USA 100(25), 14742-147477 (2003).
24. Klampfer L, Huang J, Swaby LA, Augenlicht L: Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 279(29), 30358-30368 (2004).
25. Klampfer L, Huang J, Shirasawa S, Sasazuki T, Augenlicht L: Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: the role of signal transducers and activators of transcription 1 and p21. Cancer Res. 67(18), 8477-8485 (2007).
26. Yang XJ: The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 32(3), 959-976 (2004).
27. Xu F, Zhang K, Grunstein M: Acetylation in histone H3 globular domain regulates gene expression in yeast. Cell 121(3), 375-385 (2005).
28. Williams SK, Truong D, Tyler JK: Acetylation in the globular core of histone H3 on lysine-56 promotes chromatin disassembly during transcriptional activation. Proc. Natl Acad. Sci. USA 105(26), 9000-9005 (2008).
29. Hurd PJ, Bannister AJ, Halls K et al.: Phosphorylation of histone H3 thr-45 is linked to apoptosis. J. Biol. Chem. 284(24), 16575-16583 (2009).
30. Myohanen SK, Baylin SB, Herman JG: Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 58(4), 591-593 (1998).
31. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003).
32. Fandy TE, Carraway H, Gore SD: DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J. 13(1), 40-48 (2007).
33. House MG, Herman JG, Guo MZ et al.: Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann. Surg. 238, 423-432 (2003).
34. Yang B, Guo M, Herman JG, Clark DP: Aberrant promoter methylation profles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 163, 1101-1107 (2003).
35. House MG, Guo M, Efron DT et al.: Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J. Gastrointest. Surg. 7, 1004-1014 (2003).
36. Seligson DB, Horvath S, McBrian MA et al.: Global levels of histone modifcations predict prognosis in different cancers. Am. J. Pathol. 174(5), 1619-1628 (2009).
37. Vatolin S, Navaratne K, Weil RJ: A novel method to detect functional microRNA targets. J. Mol. Biol. 358(4), 983-996 (2006).
38. Ambros V: The functions of animal microRNAs. Nature 431(7006), 350-355 (2004).
39. Johnson SM, Grosshans H, Shingara J et al.: RAS is regulated by the let-7 microRNA family. Cell 120(5), 635-647 (2005).
40. Vasudevan S, Tong Y, Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science 318(5858), 1931-1934 (2007).
41. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-myc-regulated microRNAs modulate E2F1 expression. Nature 435(7043), 839-843 (2005).
42. Takamizawa J, Konishi H, Yanagisawa K et al.: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64(11), 3753-3756 (2004).
43. Chin LJ, Ratner E, Leng S et al.: A SNP in a let-7 microRNA complementary site in the KRAS 3́ untranslated region increases non-small cell lung cancer risk. Cancer Res. 68(20), 8535-8540 (2008).
44. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T: Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 27(3), 378-386 (2008).
45. Petri A, Lindow M, Kauppinen S: MicroRNA silencing in primates: towards development of novel therapeutics. Cancer Res. 69(2), 393-395 (2009).
46. Krützfeldt j, Rajewsky N, Braich R et al.: Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005).
47. Mitchell PS, Parkin RK, Kroh EM et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
48. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112(1), 55-59 (2009).
49. Chen D, Wang CY, Lambert JD, Ai N, Welsh WJ, Yang CS: Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem. Pharmacol. 69(10), 1523-1531 (2005).
50. Fang M, Chen D, Yang CS: Dietary polyphenols may affect DNA methylation. J. Nutr. 137(1 Suppl.), S223-S228 (2007).
51. Lee WJ, Zhu BT: Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 27(2), 269-277 (2006).
52. Isakovic L, Saavedra OM, Llewellyn DB et al.: Constrained (l-)-S-adenosyl-L-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg. Med. Chem. Lett. 19(10), 2742-2746 (2009).
53. Saavedra OM, Isakovic L, Llewellyn DB et al.: SAR around (l)-S-adenosyl-L-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes. Bioorg. Med. Chem. Lett. 19(10), 2747-2751 (2009).
54. Chuang JC, Yoo CB, Kwan JM et al.: Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2́-deoxycytidine. Mol. Cancer Ther. 4(10), 1515-1520 (2005).
55. Pufulete M, Al-Ghnaniem R, Leather AJ et al.: Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 124(5), 1240-1248 (2003).
56. Song J, Medline A, Mason JB, Gallinger S, Kim YI: Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res. 60(19), 5434-5440 (2000).
57. Min/+ mouse. Carcinogenesis 25(8), 1507-1515 (2004).
58. Trasler J, Deng L, Melnyk S et al.: Impact of Dnmt1 defciency, with and without low folate diets, on tumor numbers and DNA methylation in min mice. Carcinogenesis 24(1), 39-45 (2003).
59. Figueiredo JC, Grau M V, Wallace K et al.: Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol. Biomarkers Prev. 18(4), 1041-1049 (2009).
60. Stempak JM, Sohn KJ, Chiang EP, Shane B, Kim YI: Cell and stage of transformation-specifc effects of folate defciency on methionine cycle intermediates and DNA methylation in an in vitro model. Carcinogenesis 26(5), 981-990 (2005).
61. Geisel J, Schorr H, Bodis M et al.: The vegetarian lifestyle and DNA methylation. Clin. Chem. Lab. Med. 43(10), 1164-1169 (2005).
62. Wainfan E, Poirier LA: Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res. 52(7 Suppl.), S2071-S2077 (1992).
63. Schermelleh L, Spada F, Easwaran HP et al.: Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat. Methods 2(10), 751-756 (2005).
64. Davis AJ, Gelmon KA, Siu LL et al.: Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs 21(1), 85-97 (2003).
65. Stewart DJ, Donehower RC, Eisenhauer EA et al.: A Phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann. Oncol. 14(5), 766-774 (2003).
66. Winquist E, Knox J, Ayoub JP et al.: Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada clinical trials group investigational new drug study. Invest. New Drugs 24(2), 159-167 (2006).
67. Klisovic RB, Stock W, Cataland S et al.: A Phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin. Cancer Res. 14(8), 2444-2449 (2008).
68. Robert MF, Morin S, Beaulieu N et al.: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 33(1), 61-65 (2003).
69. Brueckner B, Garcia Boy R, Siedlecki P et al.: Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 65(14), 6305-6311 (2005).
70. Watanabe-Okochi N, Kitaura J, Ono R et al.: AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111(8), 4297-4308 (2008).
71. Slape C, Liu LY, Beachy S, Aplan PD: Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl. Blood 112(5), 2017-2019 (2008).
72. Choi C W, Chung YJ, Slape C, Aplan PD: Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome. Haematologica 93(9), 1394-1397 (2008).
73. Slape C, Lin Y W, Hartung H, Zhang Z, Wolff L, Aplan PD: NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men. J. Natl Cancer Inst. Monogr. 39, 64-68 (2008).
74. Chung YJ, Choi CW, Slape C, Fry T, Aplan PD: Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell. Proc. Natl Acad. Sci. USA 105(37), 14088-14093 (2008).
75. Cheng JC, Matsen CB, Gonzales FA et al.: Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl Cancer Inst. 95(5), 399-409 (2003).
76. Cheng JC, Weisenberger DJ, Gonzales FA et al.: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell. Biol. 24(3), 1270-1278 (2004).
77. Cheng JC, Yoo CB, Weisenberger DJ et al.: Preferential response of cancer cells to zebularine. Cancer Cell 6(2), 151-158 (2004).
78. Balzarini J, Kruining J, Wedgwood O et al.: Conversion of 2́, 3́-dideoxyadenosine (ddA) and 2́, 3́-didehydro-2́, 3́-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodefciency virus and hepatitis B virus. FEBS Lett. 410(2-3), 324-328 (1997).
79. Yoo CB, Valente R, Congiatu C et al.: Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2́-deoxyzebularine. J. Med. Chem. 51(23), 7593-7601 (2008).
80. Bakker J, Lin X, Nelson WG: Methyl-CpG binding domain protein 2 represses transcription from hypermethylated p-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J. Biol. Chem. 277(25), 22573-22580 (2002).
81. Zhou Q, Atadja P, Davidson NE: Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor a (ER) gene expression without loss of DNA hypermethylation. Cancer Biol. Ther. 6(1), 64-69 (2007).
82. Lopes EC, Valls E, Figueroa ME et al.: Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer Res. 68(18), 7258-7263 (2008).
83. Yamane K, Toumazou C, Tsukada Y et al.: JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 125(3), 483-495 (2006).
84. Shi Y, Lan F, Matson C et al.: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7), 941-953 (2004).
85. Tsukada Y, Fang J, Erdjument-Bromage H et al.: Histone demethylation by a family of JmjC domain-containing proteins. Nature 439(7078), 811-816 (2006).
86. Cao R, Zhang Y: The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14(2), 155-164 (2004).
87. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplifed in cancer. EMBO J. 22(20), 5323-5335 (2003).
88. Visser HP, Gunster MJ, Kluin-Nelemans HC et al.: The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112(4), 950-958 (2001).
89. Varambally S, Dhanasekaran SM, Zhou M et al.: The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907), 624-629 (2002).
90. Miranda TB, Cortez CC, Yoo CB et al.: DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8(6), 1579-1588 (2009).
91. Tan J, Yang X, Zhuang L et al.: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007).
92. Huang Y, Greene E, Murray Stewart T et al.: Inhibition of lysine-specifc demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl Acad. Sci. USA 104(19), 8023-8028 (2007).
93. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al.: Effcacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 10(3), 223-232 (2009).
94. Silverman LR, Demakos EP, Peterson BL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group Br. J. Clin. Oncol. 20(10), 2429-2440 (2002).
95. Kantarjian H, Issa J P, Rosenfeld CS et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer 106(8), 1794-1803 (2006).
96. Raj K, John A, Ho A et al.: CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21(9), 1937-1944 (2007).
97. Fandy TE, Herman JG, Kerns P et al.: Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114(13), 2764-2773 (2009).
98. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al.: Phase 1/2 study of the combination of 5-aza-2́-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10), 3271-3279 (2006).
99. Qin T, Jelinek J, Si J, Shu J, Issa JP: Mechanisms of resistance to 5-aza-2́-deoxycytidine in human cancer cell lines. Blood 113(3), 659-667 (2009).
100. Esquela-Kerscher A, Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269 (2006).